uniQure N.V. 8-K

What Happened uniQure N.V. filed a Form 8-K (furnished June 22, 2026) to announce preliminary clinical data for AMT-260 from the first, low‑dose cohort of its Phase I/IIa trial in refractory mesial temporal lobe epilepsy. The company issued a press release on June 19, 2026; the data cutoff for the report was May 29, 2026. In the six patients treated in the low‑dose cohort (1 x 10^12 gc/mL), three patients achieved meaningful reductions in disabling seizures during months 4–6 after treatment, with declines ranging from 79% to 100%.

Key Details

• Data cutoff: May 29, 2026; press release dated June 19, 2026; 8-K filed June 22, 2026.
• Dose: low‑dose cohort at 1 x 10^12 gc/mL; n=6 patients in this cohort.
• Efficacy: 3 of 6 patients had 79%–100% reduction in disabling seizures (months 4–6); the other 3 patients had changes ranging from a 33% decrease to a 36% increase vs. baseline.
• Safety: As of June 19, 2026, no serious adverse events related to AMT‑260 or the surgical procedure reported; all adverse events in this cohort were mild or moderate (most common: headache, N=2); no immunosuppression was required.

Why It Matters These are early, preliminary human data in a small, low‑dose cohort and show both notable seizure reductions in some patients and variable responses across the group. For investors, the results provide initial evidence on both potential efficacy and a favorable short‑term safety profile (no treatment‑related serious adverse events reported). Future cohorts, larger samples and longer follow‑up will be needed to determine consistency, durability and broader safety before commercial or regulatory conclusions can be drawn.